Jade Biosciences
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Crescent St. Building 23 221 Ste 105, Wa...Phone Number
(781) 312-3013Website
www.jadebiosciences.comRevenue
-Stock Symbol
JBIOIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
3
1
1
2
2
1
About Jade Biosciences
Jade Biosciences Inc. is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, focused on developing transformative therapies to redefine the standard of care for patients living with autoimmune diseases. The company is dedicated to developing innovative, best-in-class therapies to address critical unmet needs in inflammation and immunology indications. Jade Biosciences was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine, and is the fourth company founded based on assets generated by Paragon. The company is advancing a portfolio of novel therapies that aim to transform the standard of care for patients with autoimmune diseases, with a pipeline that includes multiple development candidates and antibody discovery programs in various stages of clinical and preclinical development. Jade Biosciences operates with a focus on developing targeted therapies for indications with high unmet need across inflammation and immunologyRead more
Jade Biosciences Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Jade Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Jade Biosciences
Product Launch: Get notified when Jade Biosciences launches new products
Jade Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Jade Biosciences has new funding data
Check if Jade Biosciences has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Jade Biosciences recently announced quarterly report
Click to see if Jade Biosciences had a recent Job posting/layoffs
Check out if Jade Biosciences is spiking on competitors!
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Jade Biosciences
Find more new buyers
Company Profile Activity
Activity Insights
Jade Biosciences is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Jade Biosciences is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Jade Biosciences.
Jade Biosciences financials insights
Gather financial insights about Jade Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Other Financing Round
$95M
Jade Biosciences Tech Stack
A closer look at the technologies used by Jade Biosciences
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Jade Biosciences News & Media
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
SAN FRANCISCO and VANCOUVER, British Columbia, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the second quarter ending June 30, 2026, and provided a corporate update.Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
SAN FRANCISCO and VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the appointment of Mark Eisner, M.D., M.P.H., to its Board of Directors, effective June 25, 2026.Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN FRANCISCO and VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has closed its previously announced public offering of 11,500,000 shares of its common stock, including 1,500,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares. TheJade Biosciences Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the pricing of a public offering of 10,000,000 shares of its common stock. The shares of common stock are being sold to the public at a price of $15.00 per share. The gross proceeds to Jade from the offering, before
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Jade Biosciences
Sign Up For FreeTo access detailed company insights
Jade Biosciences Inc. is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, focused on developing transformative therapies to redefine the standard of care for patients living with autoimmune diseases. The company is dedicated to developing innovative, best-in-class therapies to address critical unmet needs in inflammat... Read More
